Carboplatin Cefmenoxime Zidovudine

References

• Koeller JM, Trump DL, Tutsch KD, Earhart RH, Davis TE, Tromey DC. Phase I Clinical Trial and Pharmacokinetics of Carboplatin (NSC 241240) by Single Monthly 30-Minute Infusion. Cancer. 1986; 57: 222–25.
   Google Scholar
• Bradner WT, Rose WC, Huftalen JB. Antitumor activity of platinium analogs. In: Prestaykko AW, Crooke ST, Carter SK, eds. Cisplatin. New York, Academic Press, 1980; 17182.
   Google Scholar
• Van Echo DA, Egorin MJ, Withacre MY, Olman EA, Aisner J. Phase I Clinical and Pharmacological Trial of Carboplatin Daily for 5 Days. Cancer Treat Rep. 1984; 68: 1103–14.
   Google Scholar
• Alberts D. Phase I trial of carboplatin-cyclophosphamide and iproplatin-cylcophosphamide in advanced ovarian cancer: A Southwest Oncology Group Study. Cancer Treat Rev. 1985; 12: 83–100.
   Google Scholar
• Sternberg C, Kelsen D, Dukeman M, Leichman L, Heelan R. Carboplatin: A New Platinum Analog in the Treatment of Epidermoid Carcinoma of the Esophagus. Cancer Treat Rep. 1985; 69: 1305–07.
   Google Scholar
• Smith IE, Evans BD. Carboplatin (JM8) as a single agent and in combination in the treatment of small cell lung cancer. Cancer Treat Rev. 1985; 12: 73–82.
   Google Scholar
• Calvert AH, Harland SJ, Newell DR et al. Early studies with cis-diammine-1, 1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol. 1982; 9: 140–47.
   Google Scholar
• Harrap KR. Pharmacokinetics of cis-diammine-1, 1-cyclobutane dicarboxylate platinum (II) in patients with normal and impaired renal function. Cancer Res. 1984; 44: 1693–97.
   Google Scholar
• Neu HC, Labthavikul P. In vitro activity and (3—lactamase stability of cefmenoxime. Antimicrob Agents Chemother. 1982, 22: 316–22.
   Google Scholar
• Labia R, Morand A, Verchere-Beaur C, Bryskier A. Affinity of Cefmenoxime for Betalactamases: An Analysis. Am J Med. 1984, 77 (suppl. 6A): 25–27.
   Google Scholar
• Fourtillan J-B, Bryskier A, Mignot A, Brosa F, Humbert G. Pharmacokinetic Study of Cefmenoxime (SCE 1365) in Healthy Adults. Am J Med. 1984, 77 (suppl. 6A): 28–31.
   Google Scholar
• Cherubin C, Nair SR. Penetration of cefmenoxirrle in the CSF as compared to cefotaxime in a small series of cases. J Antimicrob Chemother. 1984, 13: 401–02.
   Google Scholar
• Weissenbacher ER, Adams D, Gutschow K, Peters-Wclte C, Luehr HG. Clinical Results and Concentrations of Cefmenoxime in Serum, Amniotic Fluid, Mother’s Milk, and Umbilical Cord. Am J Med. 1984, 77 (suppl. 6A): 11–12.
   Google Scholar
• Gambertoglio JG, Alexander DP, Barriere SL. Cefmenoxime pharmacokinetics in healthy volunteers and subjects with renal insufficiency and on hemodialysis. Antimicrob Agents Chemother. 1984, 26: 845–49.
   Google Scholar
• Sica DA, Polk RE, Kerkering TM, Patterson P, Baggett J. Cefmenoxime kinetics during continuous ambulatory peritoneal dialysis. Eur J Clin Pharmacol. 1986, 30: 713–17.
   Google Scholar
• Baker RL, Perkins RL. Cefmenoxime: Clinical Evaluation. Am J Med. 1984, 77 (suppl. 6A): 53–9.
   Google Scholar
• Le Frock JL, Molavi A, Mc Closkey RV, Rolston, K, Chandrasekar P, Henao L et al. Cefmenoxime. Clinical, Bacteriologic, and Pharmacologic Studies. Am J Med. 1984, 77: 72–8.
   Google Scholar
• Bryskier A, Sollet JP, Bleichner G, Segrestaa JM, Guerin JM et al. Evaluation bacteriologique, clinique et cinetique de la cefmenoxime (SCE 1365) dans le traitement de soixante-. huit septicemics. Pathol Biol. 1984, 32: 34751.
   Google Scholar
• Bechard DL, Hawkins SH, Sutherland SC. Comparative Evaluation of Cefmenoxime versus Cefoxitin in Serious Infections. Am J Med. 1984, 77 (suppl. 6A): 13–6.
   Google Scholar
• Tan JS, File TM Jr. Cefmenoxime versus Cefoxitin in the Treatment of Serious Bacterial Infections. Am J Med. 1984, 77 (suppl. 6A): 51–2.
   Google Scholar
• Kawada Y, Kanimoto Y, Katoh N, Nishiura T, Naide Y et al. Comparative studies of cefmenoxime (SCE-1365) and cefazolin in complicated urinary tract infections. Chemother. (Tokyo) 1981, 29 (suppl. 1): 912–29.
   Google Scholar
• Ishigami J, Kamidono S, Kuroda Y, Kataoka N, Momose S et al. Double blind test result of cefmenoxime (SCE 1365) and cefotiam in the treatment of chronic complicated urinary tract infections. Chemother. (Tokyo) 1982, 30: 724–47.
   Google Scholar
• Stahl JP, Croize J, Bru JP, Pegouri B, Blancjouvan F et al. Diffusion de la cefmenoxime dans le liquide cephalorachidien au cours des meningites purulentes humaines. Pathol Biol. 1985, 33: 365–67.
   Google Scholar
• Balant L, Dayer P, Auckenthaler R. Clinical pharmacokinetics of the third generation cephalosporins. Clin Pharmacokin. 1985, 10: 101–43.
   Google Scholar
• Mitsuya H, Weinhold KJ, Furman PA et al. 3’-Azido-3’-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci USA. 1985, 82: 7096–100.
   Google Scholar
• Barnes DM. Promising results halt trial of antiAIDS drug. Science. 1986, 234: 15–6.
   Google Scholar
• Klecker RW, Collins JM, Yarchoan R, Thomas R, Jenkins JF, Broder S. Myers CE. Plasma and cerebrospinal fluid pharmacokinetics of 3’-Azido-3’-deoxythymidine: A novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther. 1987, 41: 407–12.
   Google Scholar
• Brook I. Approval of Zidovudine (AZT) for Acquired Immunodeficiency Syndrome. A Challenge to the Medical and Pharmaceutical Communities. JAMA. 1987, 258: 1517.
   Google Scholar
• Gill PS, Rarick M, Bryncs RK, Causey D, Lourciro C, Lcvine AM. Azidothymidine associated with bone marrow failure in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1987, 107: 502–05.
   Google Scholar
• Yarchoan R, Klecker RW, Weinhold KJ et al. Administration of 3’-Azido-3’ -deoxythymidine, an inhibitor of HTLV-LAV replication to patients with AIDS or AIDS-related complex. Lancet. 1986, 1: 575–80.
   Google Scholar